Tiotropium Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Bronchodilator
Subclass
Long-acting muscarinic antagonist (LAMA)
Speciality
Pulmonology
Schedule (India)
schedule H
Routes
Inhalation
Formulations
- Inhalation powder in hard capsules: 18 mcg per capsule (for use with HandiHaler® or equivalent device)
- Metered dose inhaler (MDI): 2.5 mcg per actuation
- Respimat® soft-mist inhaler: 2.5 mcg per puff
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Bronchodilator
| Parameter | Dry Powder Capsule (HandiHaler) | Soft-Mist Inhaler (Respimat) |
|---|---|---|
|
Starting dose
|
18 mcg once daily | 5 mcg (2 puffs) once daily |
|
Titration
|
Not applicable | Not applicable |
|
Usual maintenance dose
|
18 mcg once daily | 5 mcg (2 puffs) once daily |
|
Maximum dose
|
18 mcg/day | 5 mcg/day |
Clinical Notes:
- NOT indicated for acute bronchospasm or rescue therapy
- Administer at the same time each day
- For HandiHaler: capsule must be punctured and drug inhaled with forceful deep inspiration
- Respimat preferred for patients with poor inspiratory flow or dexterity issues
2. Asthma — Maintenance Controller (Add-on therapy when ICS + LABA insufficient)
| Parameter | Respimat Only |
|---|---|
|
Starting dose
|
5 mcg (2 puffs) once daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
5 mcg (2 puffs) once daily |
|
Maximum dose
|
5 mcg/day |
Clinical Notes:
- Reserved for moderate-to-severe asthma uncontrolled on ICS + LABA
- Requires pulmonologist supervision
- Dry powder form NOT approved for asthma in India
- Continue ICS and LABA alongside; do not use as monotherapy
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Supervision | Label Status | Evidence Basis |
|---|---|---|---|---|---|
| Bronchiectasis (non-CF) with airflow obstruction | 18 mcg once daily via HandiHaler | Long-term if benefit documented | Specialist only |
OFF-LABEL
|
Small RCTs; Indian pulmonology practice |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Age Restriction: Tiotropium Respimat is approved for children ≥6 years for asthma in some countries. INDIAN PAEDIATRIC INDICATION NOT EXPLICITLY APPROVED BY CDSCO OR IAP.
Asthma — Add-on Maintenance Therapy (Specialist Use Only)
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose | Notes |
|---|---|---|---|---|---|
| ≥6 to <12 years | 2.5 mcg (1 puff) once daily via Respimat | May increase after 4–6 weeks if inadequate response | 2.5–5 mcg once daily | 5 mcg/day |
OFF-LABEL in India
|
| ≥12 years | 5 mcg (2 puffs) once daily via Respimat | Not applicable | 5 mcg once daily | 5 mcg/day |
OFF-LABEL in India
|
Safety Monitoring:
- Monitor FEV1 response at 4–6 weeks
- Ensure adherence to ICS therapy
- Assess inhaler technique regularly
Children <6 years: NOT RECOMMENDED except in clinical trial settings
Secondary Indications — Paediatric Doses (Off-label, if any)
Not applicable.
Renal Adjustments
| eGFR (mL/min/1.73 m²) | Recommendation |
|---|---|
| ≥30 (Mild–Moderate impairment) | No dose adjustment required |
| <30 (Severe impairment) | Use with caution; monitor for anticholinergic adverse effects (dry mouth, urinary retention, constipation) due to reduced renal clearance |
| Haemodialysis | No specific data; use with caution |
Hepatic adjustment
Contraindications
- Known hypersensitivity to tiotropium, atropine, or atropine derivatives (e.g., ipratropium)
- Hypersensitivity to inhaled lactose (for dry powder capsule formulation)
- Use as rescue therapy for acute bronchospasm
Cautions
- Narrow-angle glaucoma: May precipitate or worsen acute angle-closure if mist/powder contacts eyes
- Urinary retention: Use cautiously in men with prostatic hyperplasia or bladder neck obstruction
- Moderate-to-severe renal impairment: Increased risk of systemic anticholinergic effects
- Inhalation technique: Suboptimal technique significantly reduces drug delivery and efficacy
- Do NOT nebulise: Product not designed for nebuliser use
- Paradoxical bronchospasm: Discontinue immediately if occurs
- Cardiovascular disease: Use cautiously in patients with recent myocardial infarction or unstable arrhythmia
Pregnancy
| Parameter | Recommendation |
|---|---|
|
Risk category/Safety statement
|
Limited human data; animal studies suggest low risk |
|
Preferred alternatives
|
Inhaled corticosteroids (ICS) and LABAs (e.g., budesonide, formoterol) are better studied in pregnancy |
|
When it may be used
|
When benefit clearly outweighs risk in moderate-to-severe COPD/asthma uncontrolled on other agents |
|
Monitoring
|
Pulmonary function; fetal growth on ultrasound if prolonged use |
Lactation
| Parameter | Recommendation |
|---|---|
|
Compatibility
|
Likely compatible due to minimal systemic absorption via inhalation |
|
Preferred alternatives
|
Continue if clinically necessary for disease control |
|
Expected drug levels in milk
|
Negligible (low systemic absorption) |
|
Infant monitoring
|
Observe for signs of anticholinergic exposure: poor feeding, dry mouth, irritability (unlikely) |
Elderly
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
Same as younger adults (no age-based dose adjustment) |
|
Titration
|
Not required; slower titration unnecessary unless comorbidities present |
|
Extra risks
|
Dry mouth, urinary retention, constipation, confusion — especially with severe renal impairment or anticholinergic polypharmacy |
|
Device preference
|
Respimat may be preferred over DPI in those with poor inspiratory effort |
Major drug interactions
| Interacting Drug(s) | Effect/Mechanism | Recommendation |
|---|---|---|
| Other inhaled antimuscarinics (e.g., ipratropium, glycopyrronium, umeclidinium) | Additive anticholinergic effects — increased risk of dry mouth, urinary retention, constipation, confusion |
Avoid concurrent use
|
| Systemic anticholinergics (e.g., oxybutynin, tolterodine) | Additive anticholinergic burden |
Avoid or use with extreme caution
|
Moderate drug interactions
| Interacting Drug(s) | Effect/Mechanism | Recommendation |
|---|---|---|
| Inhaled beta-agonists (salbutamol, formoterol, salmeterol) | Often co-administered; additive cardiovascular effects (tachycardia, tremor) possible | Monitor; generally safe combination |
| Inhaled corticosteroids (ICS) | Commonly used together for asthma/COPD | Safe combination; no dose adjustment |
| Potassium-lowering agents (loop/thiazide diuretics) | Hypokalaemia may increase arrhythmia risk when combined with beta-agonists | Monitor potassium if triple therapy |
| Tricyclic antidepressants, sedating antihistamines | Increased total anticholinergic burden | Monitor for adverse effects |
Note: Tiotropium is primarily renally excreted with no significant CYP450 interactions.
Common Adverse effects
- Dry mouth (xerostomia) — most frequent
- Constipation
- Cough post-inhalation
- Pharyngitis / throat irritation
- Headache
- Sinusitis
Serious Adverse effects
| Adverse Effect | Clinical Significance |
|---|---|
| Paradoxical bronchospasm | Discontinue immediately; treat as acute bronchospasm |
| Acute angle-closure glaucoma | Can occur if mist/powder contacts eye; urgent ophthalmology referral |
| Urinary retention | Particularly in elderly men with prostatic hypertrophy; may require catheterisation |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis — discontinue permanently |
| Supraventricular tachycardia / atrial fibrillation | Rare; monitor in patients with pre-existing cardiac disease |
Monitoring requirements
| Timing | Parameter |
|---|---|
|
Baseline
|
Spirometry (FEV1, FVC); symptom burden assessment (mMRC, CAT score for COPD) |
|
After initiation (4–6 weeks)
|
Assess bronchodilator response; review inhaler technique; evaluate symptom improvement |
|
Long-term
|
Monitor for dry mouth, urinary symptoms; intraocular pressure in glaucoma-prone patients; renal function if impaired at baseline |
|
Renal impairment
|
Monitor for systemic anticholinergic side effects |
Brands in India
| Spiriva® | Boehringer Ingelheim | Dry powder capsule; Respimat |
|---|---|---|
| Tiova® | Cipla | Dry powder capsule |
| Tiova Respimat® | Cipla | Soft-mist inhaler |
| T Spiriva® | Sun Pharma | Dry powder capsule |
| Tiomate® | Cipla | FDC with LABA (DPI) — note: fixed-dose combination |
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| DPI capsule (18 mcg) | ₹15–30 per capsule |
| Respimat cartridge (4 weeks supply) | ₹1,000–1,600 |
Note: May be available at subsidised rates in government settings under NLEM provisions for COPD.
Clinical pearls
- Device selection matters: Prefer Respimat for elderly patients or those with poor inspiratory flow; DPI requires forceful inhalation for adequate drug deposition.
- Technique is critical: Always verify inhaler technique at every visit — incorrect use is a common cause of treatment failure.
- Not for rescue: Tiotropium is strictly preventive/maintenance therapy; never prescribe for acute symptom relief.
- Eye protection: Advise patients to avoid spraying toward eyes, especially with Respimat — can precipitate acute glaucoma.
- Asthma positioning: In asthma, tiotropium is a Step 4/5 add-on only when ICS + LABA are insufficient; never use as monotherapy.
- Anticholinergic burden: Screen for concomitant anticholinergic medications in elderly to prevent cumulative toxicity.
Version
RxIndia v1.0 — 19 Jun 2025
Reference
-
- CDSCO (Form 45 and product inserts)
- Indian Pharmacopoeia / National Formulary of India (IP/NFI) 2021
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- ICMR COPD Management Guidelines
- Indian Chest Society Expert Guidelines
- AIIMS Formulary and Clinical Protocols
- Select RCTs/meta-analyses (for off-label bronchiectasis and paediatric asthma use)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.